Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood Cancer J. 2014 Mar 7;4:e189. doi: 10.1038/bcj.2014.8.

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.

Author information

1
Division of Hematology, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
2
Department of Hematology, Rikshospitalet, Oslo, Norway.
3
Department of Hematology, Århus University Hospital, Århus, Denmark.
4
Karolinska Institutet, Institution for Medicine, Stockholm, Sweden.
5
Department of Medicine, Sunderbyn Hospital, Luleå, Sweden.
6
Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden.
7
Department of Medicine, SöDersjukhuset, Stockholm, Sweden.
8
Department of Hematology, Herlev University Hospital, Copenhagen, Denmark.
9
Department of Hematology, Rigshospitalet University Hospital, Copenhagen, Denmark.
10
Department of Hematology, Odense University Hospital, Odense, Denmark.
11
Department of Hematology, Lund University Hospital, Lund, Sweden.
12
Department of Medicine and University of Bergen, K2 Clinical Institute 2, Haukeland University Hospital, Bergen, Norway.

Abstract

This prospective phase II study evaluated the efficacy of azacitidine (Aza)+erythropoietin (Epo) in transfusion-dependent patients with lower-risk myelodysplastic syndrome (MDS). Patients ineligible for or refractory to full-dose Epo+granulocyte colony stimulation factors for >8 weeks and a transfusion need of 4 units over 8 weeks were included. Aza 75 mg m(-2) d(-1), 5/28 days, was given for six cycles; non-responding patients received another three cycles combined with Epo 60 000 units per week. Primary end point was transfusion independence (TI). All patients underwent targeted mutational screen for 42 candidate genes. Thirty enrolled patients received one cycle of Aza. Ten patients discontinued the study early, 7 due to adverse events including 2 deaths. Thirty-eight serious adverse events were reported, the most common being infection. Five patients achieved TI after six cycles and one after Aza+Epo, giving a total response rate of 20%. Mutational screening revealed a high frequency of recurrent mutations. Although no single mutation predicted for response, SF3A1 (n=3) and DNMT3A (n=4) were only observed in non-responders. We conclude that Aza can induce TI in severely anemic MDS patients, but efficacy is limited, toxicity substantial and most responses of short duration. This treatment cannot be generally recommended in lower-risk MDS. Mutational screening revealed a high frequency of mutations.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center